Last updated 2026-08-21
- Raised $200M Follow-on PO, Aug 2026
- Raised $100M Follow-on PO, Jun 2026
- Raised $60M Follow-on PO, May 2025
Total raised
$420.7M
Stage
—
Founded
2020
Headcount
—
HQ
Fort Lee, United States
Sector
Healthcare
About
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious conditions with unmet medical needs in oncology and complement-related conditions. The company's pipeline includes NXP100, a complement Factor B inhibitor, and two kinase inhibitors, NXP900 and NXP200, for advanced cancers. Nuvectis Pharma operates with a capital-efficient, virtual business model, in-licensing promising therapeutics and advancing them through clinical development.
Funding history · 7 rounds · $420.7M total
2026-08
Follow-on PO
$200.0M
2026-06
Follow-on PO
$100.0M
2025-05
Follow-on PO
$60.0M
2025-02
Follow-on PO
$13.5M
2022-07
PIPE
$15.9M
2022-02
IPO
$16.0M
2021-08
A Round
$15.3M
★ CRT Pioneer Fund★ Sixth Element Capital
Q&A
- When was Nuvectis Pharma Inc. founded?
- Nuvectis Pharma Inc. was founded in 2020.
- What is Nuvectis Pharma Inc.'s primary sector?
- Nuvectis Pharma Inc.'s primary sector is Healthcare, specifically Biotechnology, Biopharmaceuticals, and Oncology/Cancer Treatment.
- Who are the co-founders of Nuvectis Pharma Inc.?
- The co-founders of Nuvectis Pharma Inc. are Ron Bentsur, Enrique Poradosu, and Shay Shemesh.
- What is Nuvectis Pharma Inc.'s business model?
- Nuvectis Pharma Inc. operates with a capital-efficient, virtual business model, in-licensing promising therapeutics and advancing them through clinical development.
- When did Nuvectis Pharma Inc. complete its Series A funding round and who were the lead investors?
- In August 2021, Nuvectis Pharma Inc. completed an A Round totaling $15,300,000. The lead investors were CRT Pioneer Fund and Sixth Element Capital.
- When did Nuvectis Pharma Inc. go public?
- Nuvectis Pharma Inc. completed an IPO in February 2022, raising $16,000,000.
- What was the amount raised in Nuvectis Pharma Inc.'s PIPE financing round?
- In July 2022, Nuvectis Pharma Inc. raised $15,900,000 through a PIPE financing round.
- What was the most recent follow-on public offering by Nuvectis Pharma Inc.?
- Nuvectis Pharma Inc. completed a follow-on public offering in August 2026, raising $200,000,000.
- What is the total amount of funding raised by Nuvectis Pharma Inc.?
- Nuvectis Pharma Inc. has raised a total of $420,700,000 across all funding rounds.
Team · 9
Ron Bentsur
Founder · Co-Founder, Chairman, CEO & President
Enrique Poradosu
Founder · Co-Founder, Executive Vice President, Chief Scientific and Business Officer
Shay Shemesh
Founder · Co-Founder, Executive Vice President, Chief Development & Operations Officer
Kenneth Hoberman
Independent Director
James F. Oliviero, III
Independent Director
Matthew Lee Kaplan
Independent Director
Juan Fernando Sanchez
Independent Director
Shannon N. Westin
Member of Scientific Advisory Board
Paul Workman
Member of Scientific Advisory Board
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nuvectis.com |
|---|
Identifiers & details
| Legal name | Nuvectis Pharma, Inc. |
|---|---|
| Founded | 2020 |